000143668 001__ 143668
000143668 005__ 20240229112602.0
000143668 0247_ $$2doi$$a10.1093/annonc/mdz121
000143668 0247_ $$2pmid$$apmid:31089709
000143668 0247_ $$2ISSN$$a0923-7534
000143668 0247_ $$2ISSN$$a1569-8041
000143668 0247_ $$2altmetric$$aaltmetric:58826730
000143668 037__ $$aDKFZ-2019-01242
000143668 041__ $$aeng
000143668 082__ $$a610
000143668 1001_ $$aSmith Byrne, K.$$b0
000143668 245__ $$aThe role of plasma microseminoprotein-beta in prostate cancer: an observational nested case-control and Mendelian randomization study in the European prospective investigation into cancer and nutrition.
000143668 260__ $$aOxford$$bOxford Univ. Press$$c2019
000143668 3367_ $$2DRIVER$$aarticle
000143668 3367_ $$2DataCite$$aOutput Types/Journal article
000143668 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1566563939_30392
000143668 3367_ $$2BibTeX$$aARTICLE
000143668 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143668 3367_ $$00$$2EndNote$$aJournal Article
000143668 520__ $$aMicroseminoprotein-beta (MSP), a protein secreted by the prostate epithelium, may have a protective role in the development of prostate cancer. The only previous prospective study found a 2% reduced prostate cancer risk per unit increase in MSP. This work investigates the association of MSP with prostate cancer risk using observational and Mendelian randomization (MR) methods.A nested case-control study was conducted with the European Prospective Investigation into Cancer and Nutrition (EPIC) with 1871 cases and 1871 matched controls. Conditional logistic regression analysis was used to investigate the association of pre-diagnostic circulating MSP with risk of incident prostate cancer overall and by tumour subtype. EPIC-derived estimates were combined with published data to calculate an MR estimate using two-sample inverse-variance method.Plasma MSP concentrations were inversely associated with prostate cancer risk after adjusting for total prostate-specific antigen concentration [odds ratio (OR) highest versus lowest fourth of MSP = 0.65, 95% confidence interval (CI) 0.51-0.84, Ptrend = 0.001]. No heterogeneity in this association was observed by tumour stage or histological grade. Plasma MSP concentrations were 66% lower in rs10993994 TT compared with CC homozygotes (per allele difference in MSP: 6.09 ng/ml, 95% CI 5.56-6.61, r2=0.42). MR analyses supported a potentially causal protective association of MSP with prostate cancer risk (OR per 1 ng/ml increase in MSP for MR: 0.96, 95% CI 0.95-0.97 versus EPIC observational: 0.98, 95% CI 0.97-0.99). Limitations include lack of complete tumour subtype information and more complete information on the biological function of MSP.In this large prospective European study and using MR analyses, men with high circulating MSP concentration have a lower risk of prostate cancer. MSP may play a causally protective role in prostate cancer.
000143668 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000143668 588__ $$aDataset connected to CrossRef, PubMed,
000143668 7001_ $$aAppleby, P. N.$$b1
000143668 7001_ $$aKey, T. J.$$b2
000143668 7001_ $$aHolmes, M. V.$$b3
000143668 7001_ $$aFensom, G. K.$$b4
000143668 7001_ $$aAgudo, A.$$b5
000143668 7001_ $$aArdanaz, E.$$b6
000143668 7001_ $$aBoeing, H.$$b7
000143668 7001_ $$aBueno-de-Mesquita, H. B.$$b8
000143668 7001_ $$aChirlaque, M. D.$$b9
000143668 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, R.$$b10$$udkfz
000143668 7001_ $$aLarrañaga, N.$$b11
000143668 7001_ $$aPalli, D.$$b12
000143668 7001_ $$aPerez-Cornago, A.$$b13
000143668 7001_ $$aQuirós, J. R.$$b14
000143668 7001_ $$aRicceri, F.$$b15
000143668 7001_ $$aSánchez, M. J.$$b16
000143668 7001_ $$aTagliabue, G.$$b17
000143668 7001_ $$aTsilidis, K. K.$$b18
000143668 7001_ $$aTumino, R.$$b19
000143668 7001_ $$aFortner, R. T.$$b20
000143668 7001_ $$aFerrari, P.$$b21
000143668 7001_ $$aConsortium, PRACTICAL$$b22$$eCollaboration Author
000143668 7001_ $$aRiboli, E.$$b23
000143668 7001_ $$aLilja, H.$$b24
000143668 7001_ $$aTravis, R. C.$$b25
000143668 773__ $$0PERI:(DE-600)2003498-2$$a10.1093/annonc/mdz121$$gp. mdz121$$n6$$p983-989$$tAnnals of oncology$$v30$$x1569-8041$$y2019
000143668 909CO $$ooai:inrepo02.dkfz.de:143668$$pVDB
000143668 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000143668 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000143668 9141_ $$y2019
000143668 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000143668 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143668 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143668 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143668 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000143668 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bANN ONCOL : 2017
000143668 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000143668 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000143668 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143668 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000143668 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143668 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143668 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000143668 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bANN ONCOL : 2017
000143668 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x0
000143668 980__ $$ajournal
000143668 980__ $$aVDB
000143668 980__ $$aI:(DE-He78)C020-20160331
000143668 980__ $$aUNRESTRICTED